| Idiopathic pulmonary fibrosis (IPF) remains a fatal and incurable disease despite the use of approved antifibrotic drugs. |
| Development of novel antifibrotics drugs has consistently increased over the last decades, but unsolved issues remain about endpoints, duration, and inclusion/exclusion criteria of future clinical trials. |
| A better knowledge of mechanisms leading to IPF onset and progress is crucial to the development of new compounds. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.